课件:腹腔感染细菌学特点及抗生素治疗策略.ppt

课件:腹腔感染细菌学特点及抗生素治疗策略.ppt

  1. 1、本文档共48页,可阅读全部内容。
  2. 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
课件:腹腔感染细菌学特点及抗生素治疗策略.ppt

刚才提到的这些常见的复杂腹腔感染性疾病多为社区获得性腹腔感染,它们的病原学特点如下 在上消化道: 以肠道杆菌科细菌为主(大肠埃希菌,克雷伯菌属,肠杆菌属);厌氧菌的检出也逐渐增多 在下消化道: 除肠道杆菌科细菌外,厌氧菌明显增多,主要是拟杆菌,尤其是脆弱拟杆菌 * CR = 碳青酶烯耐药 Int J Antimicrob Agents.?2012 Jun;40 Suppl:S4-10. doi: 10.1016/S0924-8579(12)70003-1. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010. Huang CC1,?Chen YS,?Toh HS,?Lee YL,?Liu YM,?Ho CM,?Lu PL,?Liu CE,?Chen YH,?Wang JH,?Tang HJ,?Yu KW,?Liu YC,?Chuang YC,?Xu Y,?Ni Y,?Ko WC,?Hsueh PR. Author information Abstract This study examined the rates of susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates that had been obtained from patients with intraabdominal infections in the Asia-Pacific region as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Susceptibility profiles obtained using 2009 Clinical and Laboratory Standards Institute (CLSI) breakpoints were compared with those obtained using the 2011 CLSI breakpoints. From 2002 to 2010, Escherichia coli and Klebsiella pneumoniae together accounted for more than 60% of the 13714 Enterobacteriaceae isolates analyzed during the study period. Extended-spectrum β-lactamase (ESBL) producers comprised 28.2% of E. coli isolates and 22.1% of K. pneumoniae isolates in the Asia-Pacific region, with China (55.6% and 33.7%, respectively) and Thailand (43.1% and 40.7%, respectively) having the highest proportions of ESBL producers. Based on the 2011 CLSI criteria, 77.2% of the Enterobacteriaceae isolates, 40.4% of ESBL-producing E. coli, and 25.2% of ESBL-producing K. pneumoniae isolates were susceptible to ceftazidime. Carbapenems showed in vitro activity against 90% of Enterobacteriaceae isolates in all participating countries, except for ertapenem in South Korea (susceptibility rate 82.2%). Marked differences (5%) in su

文档评论(0)

iuad + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档